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Oligomerization, conformational changes, and the consequent neurodegeneration of Alzheimer’s β-amyloid protein (AβP) play
crucial roles in the pathogenesis of Alzheimer’s disease (AD). Mounting evidence suggests that oligomeric AβPs cause the
disruption of calcium homeostasis, eventually leading to neuronal death. We have demonstrated that oligomeric AβPs directly
incorporate into neuronal membranes, form cation-sensitive ion channels (“amyloid channels”), and cause the disruption of
calcium homeostasis via the amyloid channels. Other disease-related amyloidogenic proteins, such as prion protein in prion
diseases or α-synuclein in dementia with Lewy bodies, exhibit similarities in the incorporation into membranes andthe formation
of calcium-permeable channels. Here, based on our experimental results and those of numerous other studies, we review the
current understanding of the direct binding of AβP into membrane surfaces and the formation of calcium-permeable channels.
The implication of composition of membrane lipids and the possible development of new drugs by inﬂuencing membrane
properties and attenuating amyloid channels for the treatment and prevention of AD is also discussed.
1.Introduction
Alzheimer’s disease (AD) is a severe type of senile dementia,
aﬀecting a large portion of elderly people worldwide. It is
characterized by profound memory loss and inability to
form new memories. The pathological hallmarks of AD are
the presence of numerous extracellular deposits, termed
senile plaques, and intraneuronal neuroﬁbrillary tangles
(NFTs). The degeneration of synapses and neurons in the
hippocampus or cerebral cortex is also observed [1]. The
major components of NFTs are phosphorylated tau proteins,
and that of senile plaques are β-amyloid proteins (AβPs).
Althoughthe precisecause ofADremains elusive,itis widely
accepted that oligomerization of AβPa n dt h ec o n s e q u e n t
neurodegeneration might be the cause of neuronal death in
AD patients [2, 3].
There is considerable interest regarding the mechanism
by which AβPs cause neurodegeneration. AβPs have been
reported to cause various adverse eﬀects on neuronal
survivals, such as the production of reactive oxygen species,
the induction of cytokines, the induction of endoplasmic
reticulum (ER) stresses, and the abnormal increase in
intracellular calcium levels ([Ca2+]i)[ 4]. These adverse
eﬀects are complex and may be interwoven. Of these eﬀects,2 International Journal of Alzheimer’s Disease
the disruption of calcium homeostasis could be the earliest
and primary event, since Ca2+ ions are essential for various
neuronal functions. The elevation of [Ca2+]i induces various
apoptotic pathways.
There are several mechanisms that account for AβP-
inducedcalciumdyshomeostasis[5–7].Ofthese,wefocuson
the “amyloid channel hypothesis”—direct insertion into
membranes of AβP, formation of channels (pores), and
disruption of calcium homeostasis viaunregulated cytotoxic
channels may be the molecular basis of its neurotoxicity [8–
10]. Other amyloidogenic disease-related proteins, such as
the prion protein or α-synuclein, also exhibit similarities in
the formation of amyloid channels and in the disruption of
calcium homeostasis.
We review here the current understanding of the “amy-
loid channel hypothesis” based on our recent results and
those of other researchers. It is widely recognized that the
composition of membrane lipids inﬂuences the formation
of amyloid channels by aﬀecting the interaction between
peptides and membranes. The possible development of new
drugs by inﬂuencing membrane lipid properties and attenu-
ating amyloid channels for the treatment and prevention of
AD is also discussed.
2.ConformationalChangesof
AβPan dI tsN e ur o t o x icity
AβP is a small peptide with 39–43 amino acid residues. It is
secreted by the cleavage of the N-terminal of a large
precursor protein (amyloid precursor protein; APP) by β-
secretase (β-site APP cleaving enzyme; BACE), followed
by the intramembrane cleavage of its C-terminal by γ-
secretase. This diﬀerent C-terminal cleavage of APP causes
various truncated AβPs, such as AβP(1–40), the ﬁrst 40
amino acid residues, or AβP(1–42). Genetic studies of early-
onset cases of familial AD indicated that APP mutations
and AβP metabolism are associated with AD [11]. It was
also revealed that mutations in the presenilin genes account
for the majority of cases of early-onset familial AD [12].
Presenilins have been revealed to be γ-secretases [13], and
their mutations inﬂuence the production of AβPa n di t s
neurotoxicity [14].
Yankner et al. reported that AβP(1–40) caused the death
of cultured rat hippocampal neurons or neurodegeneration
in the brains of experimental animals [15]. However, the
neurotoxicity of AβP has been a subject of much debate
because of its peculiar characteristics. AβPi sah y d r o p h o b i c
peptide with an intrinsic tendency to self-assemble to form
oligomers (aggregates). In the aqueous solution, monomeric
form of AβP exhibits a random coil structure. Meanwhile,
underincubationat37◦Cf ors ev era lda ys(aging),AβPs form
aggregates (oligomers) with β-pleated sheet structures. Pike
et al. revealed that aged AβP(1–40) was considerably more
toxic to cultured neurons as compared to freshly prepared
AβP(1–40) [16]. The neurotoxicity of AβP was correlated
withtheirβ-sheet contents,asobservedbycirculardichroism
(CD) spectroscopy [17]. Jarrett and Lansbury demonstrated
thatAβPformsoligomersbyanucleation-dependentprocess
and that AβP(1–42) becomes “seeds” in the aggregates and
enhances the oligomerization of AβP(1–40)—suggesting the
signiﬁcance of intracellular N- and C-terminal heterogeneity
[18].
Recent detailed analysis using size-exclusion chromatog-
raphy, gel electrophoresis, and atomic force microscopy
(AFM) has demonstrated that there are several stable types
of soluble oligomers: naturally occurring soluble oligomers
( d i m e r so rt r i m e r s ) ,A D D L s( A βP-derived diﬀusible lig-
ands), AβP globulomers, or protoﬁbrils. Increasing evidence
suggests that soluble amyloid oligomers cause synaptic and
neuronal degeneration [19–21]. The identiﬁcation of toxic
AβP spices is crucial and has been a subject of scientiﬁc
debates. Hartley et al. separated aggregated AβP(1–40)
into low-molecular-weight (mainly monomer), protoﬁbril-
lar, and ﬁbril fractions by size-exclusion chromatography,
and found that the protoﬁbrillar fraction caused marked
changes in the electrical activity of cultured neurons and
neurotoxicity [22]. Walsh et al. reported that the nat-
urally secreted (derived from the cerebrospinal ﬂuid of
AD patients), SDS-stable low-molecular-weight oligomers
(dimers, trimers, or tetramers), but not AβP monomers
or larger aggregates, inhibit long-term potentiation (LTP)
and cause the loss of dendritic spines and synapses [23].
Lacor and colleagues reported that AβP-derived diﬀusible
ligands (ADDLs) inhibited LTP and exhibited adverse eﬀects
on synaptic plasticity, such as abnormal spine morphology,
decreased spine density, and decreased synaptic proteins
[24]. Recently, Jan et al. found that mixtures of monomeric
and heterogenous oligomers AβP(1–42) were more toxic
than monomeric, protoﬁbrillar fractions or ﬁbril [25]. They
demonstrated that AβP toxicity depends on the ability to
grow and undergo ﬁbril formation of preﬁbrillar aggregates
and monomer. The process of ﬁbril formation and its
contribution to toxicity is complicated. Mature ﬁbrils are
regarded to be less toxic compared to soluble oligomers
[26, 27], although there are some cases ﬁbrils direct cause
toxicity [28, 29]. It is possible that the toxicity of mature
ﬁbrils can result from the leakage of toxic short protoﬁbrils
or oligomers [27] or from its size-dependent mechanical
properties of accumulations in the normal tissues [30].
As synaptic plasticity is crucial for the process of mem-
ory formation, synaptic degeneration (synaptotoxicity) is
involved in the early stages of AD. Indeed, the number of
synapses is strongly correlated with the level of memory
impairment in AD patients, rather than the number of senile
plaques or NFTs, [31]. Considering that AβPi ss e c r e t e di n
the cerebrospinal ﬂuid (CSF) of young individuals as well
as in aged or dementia patients [32], factors that accelerate
or inhibit the oligomerization may play essential roles in the
pathogenesis of AD. Various factors, such as the concentra-
tionofpeptides,theoxidations,mutations,andracemization
of AβP, pH, composition of solvents, temperature, and trace
elements, can inﬂuence the oligomerization processes [33].
Among these factors, Al and other trace elements are of
particular interest because of the epidemiological link with
AD [34].International Journal of Alzheimer’s Disease 3
3.AβP-Induced Neurotoxicity and
the DisruptionofCalciumHomeostasis
There is considerable interest regarding in the mechanism
by which AβPs cause neurodegeneration. Of various adverse
eﬀects caused by AβP, calcium dyshomeostasis could be the
earliest and primary adverse event,since Ca2+ ions are essen-
tial for various key enzymes such as kinases, phosphatases,
and proteases. Once neuronal calcium homeostasis was dis-
rupted and [Ca2+]i was changed, various apoptotic pathways
such as calpain and caspase activation occurred, leading
to neuronal death. The disruption of calcium homeostasis
could trigger the membrane disruption, the formation of
reactive oxygen species (ROS), and induce other adverse
eﬀects which are often observed after exposure to AβP. It is
widely known that the increase in [Ca2+]i induced changes
in the number of spines, their morphology, and the number
of synapses [35]. Considering that AβPa n dA P Pc o e x i s t
in the synapses [36], calcium imbalances in the synaptic
compartment could directly inﬂuence neuronal activities
and cause synaptic impairment (synaptotoxicity). Ca2+ is
also implicated in the phosphorylation of the tau protein
[37]o ri nA P Ps e q u e s t r a t i o n[ 38]. Fibroblasts derived from
AD patients exhibited diﬀerent Ca2+ mobilization compared
to those derived from age-matched control subjects [39].
Mounting evidence indicates that calcium dysregulation
occurs in AD or in AβP-intoxicated neurons [40, 41].
There are several possible mechanisms by which AβPs
interact with neurons and disrupt calcium homeostasis.
Demuro et al. reviewed the AβP-induced calcium dyshome-
ostasis and its toxicity in the context of calcium signaling,
andoutlinedthreemajormechanisms: theactivationofsome
type of cell surface receptors coupled to Ca2+ inﬂux, the dis-
ruption of membrane integrity, and the direct incorporation
into the membrane to create unregulated cytotoxic channels
(pores) [5].
AβPs were reported to bind to NMDA (N-methyl D-
aspartate-)type or AMPA (α-amino-3-hydroxy-5-methy-lis-
oxazole4-propionic acid)-type glutamate receptors [42], or
nicotinic acetylcholine receptors [43]. All of these receptors
were highly Ca2+ permeable. Furthermore, AβP inﬂuences
voltage gated Ca2+ channels [44] or inositol triphosphate
(IP3) receptor [45]. It is widely recognized that presenilins
are involved in capacitative Ca2+ entry, in ER Ca2+ signaling,
or in mitochondrial Ca2+ signaling, and that their mutations
aﬀect the calcium-regulated functions [46–49]. Therefore,
disturbances of ER Ca2+ stress or mitochondrial Ca2+
homeostasis may be involved in the pathogenesis of AD.
4.Channel Formationby AβP:Possible
Mechanisms of CalciumDyshomeostasis
In 1993, Arispe et al. ﬁrst demonstrated that AβP(1–40)
directly incorporates into artiﬁcial planar lipid bilayer
membranes and forms cation selective ion channels [50,
51]. These “amyloid channels” were revealed to be giant
multilevel pores and were permeable to Ca2+.T h e i ra c t i v i t y
was blocked by Zn2+, which is abundantly present in the
brain [52]. Other neurotoxic peptide fragments of AβP,
including AβP(25–35) and AβP(1–42), were reported to
form calcium-permeable pores on artiﬁcial lipid bilayers as
well as AβP(1–40) [53, 54]. The characteristics of amyloid
channels formed by AβP(1–40) and AβP(1–42) exhibited
similarities: multilevel and giant pores (∼5nS) and cation
(including Ca2+) selectivity. The activity of both channels
could be blockedby Zn2+.F r a s e re ta l . reported that the toxic
C-terminal fragment of APP(CT105; containing a full length
ofAβP) inducedchannel currentsonmembranes of Xenopus
oocytes [55].
Durell et al. proposed a 3D structural model of amyloid
channels obtained from a computer simulation of the
secondary structure of AβP(1–40) in membranes, which
showed 5 to 8 mers aggregating to form pore-like structures
on the membranes [56]. Strodel et al. proposed a model of
AβP(1–42) pores which consist of tetrameric and hexameric
β-sheet subunits from the observations in NMR [57]. These
models are consistent with morphological observations
using high-resolution AFM that demonstrated that AβPs
form pore-like structures on mica plates or on membranes
[58–60].
A large number of studies have demonstrated that AβP
directlybindstomembranes, causesmembraneperturbation
or disruption, and induces the increase in permeability
to ions (including Ca2+) or large molecules [61–64]. The
ﬁndings of Demuro et al. are particularly interest in this
context [65]. They investigated eﬀects of AβPa n do t h e r
amyloid peptides in various aggregation states, and revealed
that oligomeric peptides caused the rapid increase in [Ca2+]i
or the membrane disruption, whereas monomers and ﬁbrils
did not.
Furthermore,thepresenceofpore-likestructuresofAβPs
was demonstrated in the neuronal cell membrane of the
brains of AD patients and of AD-model mice. Using high-
resolutiontransmission electronmicroscopy,Inoueobserved
in situ AβP pores in the neuronal cell membrane in AD
brains[66].Kayedetal.reportedthattheannularprotoﬁbrils
(APFs) of AβP exhibit ring-shaped and pore-like structures
[67].Theage-dependentaccumulationofAPFswasobserved
on the membranes of AD model mice (APP transgenic mice;
APP23) [68].
To determine whether or not AβPs form channels on
neuronal cell membranes as well as on artiﬁcial lipid
bilayers, we employed membrane patches from immortal-
ized hypothalamic neurons (GT1-7 cells). GT1-7 cells are
derived from murine hypothalamic neurons by site-directed
tumorigenesis and exhibit various neuronal characteristics,
such as the extension of neuritis, and the expression of
variousneuron-speciﬁc proteinsorreceptors[69].Within3–
30min oftheaddition ofAβP(1–40)tothe bathsolution,the
current derived from the amyloid channels appeared across
the excised membrane patches [70]. However, AβP(40–1), a
peptide bearing the reversed sequence of AβP(1–40), did not
form any channels. The characteristics of amyloid channels
formed on the GT1-7 cell membranes were considerably
similar to those observed on artiﬁcial lipid bilayers: cation
selective, multilevel, voltage independent, and long-lasting.
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and recovered by a zinc chelator–o-phenanthroline. Further-
more, Sepulveda et al. revealed that AβP(1–40) formed per-
forations on membranes excised from hippocampal neurons
and induced currents [71]. The eﬀect of AβPw a ss i m i l a rt o
that of gramicidin and amphotericin which are commonly
used to perforate neuron membranes.
5.Disruptionof CalciumHomeostasis
Causedby AmyloidChannels
In order to test the validity of the amyloid channel hy-
pothesis, we examined whether AβPa l t e r st h e[ C a 2+]i lev-
els of GT1-7 cells under the same conditions, using
a high-resolution multisite video imaging system with
calcium-sensitive ﬂuorescent dye, fura-2 [71–74]. Shown in
Figure 1(a) are pseudocolor images of levels indicating
the [Ca2+]i of GT1-7 cells before and after exposure to
AβP(1–40). Shortly after exposure to AβP(1–40), a marked
increase in [Ca2+]i occurred among many, but not all
GT1-7 cells. Figure 1(b) depicts AβP(1–40)-induced tempo-
ral changes of the [Ca2+]i of 50 randomly chosen GT1-7
cells in the same ﬁeld of view. Furthermore, we compared
responses to AβP and the related peptides (Figure 2(a)).
Althoughamarkedincrease in[Ca2+]i was causedbyAβP(1–
40) (line (A))o rb yA βP(1–42) (line (C)), control peptides
such as AβP(40-1) caused no remarkable changes (line (B)).
As previously discussed, there are several mechanisms
that could account for the elevations in [Ca2+]i induced by
AβP. However, our detailed quantitative analysis of the AβP-
induced calcium inﬂux suggests that AβP-induced [Ca2+]i
changes occurred via unregulated amyloid channels and
not by endogenous receptor-mediated pathways. This is
supported by 4 major pieces of evidence.
First,t h eA βP-induced [Ca2+]i rise was highly het-
erogeneous among genetically identical GT1-7 cells. Even
in the same ﬁeld of view, exposure to the same peptide
solution produced diﬀerent change patterns in the [Ca2+]i
levelsas shown in Figure 1(b). AlthoughAβP(1–40) induced
an increase in the [Ca2+]i levels either instantly or after
some delay, the magnitude and latency diﬀered. Certain
other adjacent cells still did not exhibit any responses. It is
possible that the membrane binding of AβPi sc r u c i a lf o r
the cell-to-cell heterogeneity. Simakova and Arispe revealed
that the surface phosphatidylserine and the cytosolic ATP
levels are important determinants of the binding of AβP
to membranes [75]. To analyze AβP-induced calcium inﬂux
quantitatively under the cell-to-cell heterogeneous condi-
tion, we compared the peak increase in [Ca2+]i (Δ[Ca2+]i)
induced by AβPs and its latency (the lag between the [Ca2+]i
increase and the time of AβP addition) in each cell. This
multisite ﬂuorometry system enables the simultaneous long-
term observation of temporal changes in [Ca2+]i of more
than 50 neurons. Second,t h ea v e r a g eΔ[Ca2+]i was increased
in a dose-dependent manner of AβP, while the average
latency decreased (Figures 2(b) and 2(c)). It is unlikely
that the dose-dependent decrease in the latency occurs
through the receptor-mediated pathways. These features are
considerably similar to those observed in relation to peptide
channels formed on membranes [71, 76]. The concentration
of AβP required to form amyloid channels is higher (∼μM)
than the AβP concentration found in the brain. However,
it is plausible that it requires a longer period for the lower
concentration of AβP to cause changes in [Ca2+]i.
Third,t h eA βP-induced increase in [Ca2+]i was notinﬂu-
enced by the addition of the Na+ channel blocker (tetrodo-
toxin), the Ca2+ channel blocker (nifedipine), the antagonist
of NMDA-type glutamate receptor (D-APV), or the antag-
onist of γ-aminobutyric acid (GABA) receptor (bicuculline)
[77].
Fourth,D - A βP(1–40), AβP(1–40) composed of all D-
amino acid residues, also caused the elevation of [Ca2+]i in
a manner similar to AβP(1–40) (Figure 2(a) line (D)). This
is consistent with the ﬁndings of Cribbs et al. suggesting
that all-D-enantiomers of AβP possess the similar toxicity
compared to all-L- AβP[ 78].
Therefore, it is plausible that AβP-induced [Ca2+]i
changes occurred through amyloid channels by direct incor-
poration into membranes, but not through some receptor-
mediated pathways.
These results strongly support the hypothetical idea
termed“amyloid channel hypothesis,” namely, thatthedirect
incorporation of AβPs and the subsequent imbalances of
calciumandotherionsthroughamyloid channels maybethe
primary event in AβPn e u r o t o x i c i t y[ 8–10].
6.Channel Formationand [Ca2+]i Inﬂux by
Other AmyloidogenicPeptides
Pore formation-induced cytotoxicity, such as in the cases
of certain toxins or venoms, is commonly observed in our
biological system. Forexample, the α-toxin of Staphylococcus
aureus, which is secreted as a single-chain, water-soluble
33kDa molecule, nonspeciﬁcally binds to membranes to
form pore-like structures composed of hexamers with β-
sheet structures, causing Ca2+ inﬂux through the pores [79].
Magainin 2, a 26-residue antimicrobial peptide obtained
from Xenopus laevis, forms transmembrane Ca2+-permeable
pores on bacterial cell membranes [80]. Other antimicrobial
peptides such as melitin (a bee venom composed of 28
amino acids), or antibiotics such as amphotericin and
gramicidin were also reported to form transmembrane pores
and to cause cell lysis [81]. In this respect, AβPa n do t h e r
amyloidogenic proteins might share the similar mechanism
with these pore-forming peptides. Indeed, Soscia et al.
demonstrated that AβP exerts antimicrobial activity against
8 common and clinically relevant microorganisms [82].
Furthermore, electrophysiological and morphological
studies have revealed that other disease-related proteins—
termed amyloidogenic proteins—exhibit similarities in the
formation of amyloid channels as well as AβP.
Priondiseases, includinghuman kuru,Creutzfeldt-Jakob
disease, and bovine spongiform encephalopathy (BSE), are
associated with the conversion of a normal prion protein
(PrPC) to an abnormal scrapie isoform (PrPSC)[ 83]. The β-
sheet region of PrPSC is suggested to play a crucial role in
its transmissible degenerative processes. A peptide fragmentInternational Journal of Alzheimer’s Disease 5
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Figure 1: Eﬀects of AβP on temporal changes of [Ca2+]i.( a )P s e u d o c o l o ri m a g e so f[ C a
2+]i during exposure to AβP(1–40) in GT1-7 cells. A
solution of AβP(1–40) (10μM) was applied onto fura-2-loaded GT1-7 cells. Temporal changes of ﬂuorescence intensities corresponding to
increasesin[Ca2+]i were analyzed. (A) 1minbefore exposure to AβP(1–40);(B)20secafterexposure; (C)5minafterexposure. (b)Temporal
changes of randomly chosen 50 GT1-7 cells in the same ﬁeld of view before and after the exposure to AβP(1–40) are depicted. The arrow
indicates the time of peptide addition.
of PrP corresponding to residues 106–126 (PrP106–126)
coincides with the proposed β-sheet structures and has
been reported to cause death in cultured hippocampal
neurons [84]. Lin et al. reported that PrP106–126 forms
cation permeable pores in artiﬁcial lipid bilayers [85]. The
activity of PrP channels was also blocked by Zn2+.K o u r i e
and Culverson investigated the detailed characteristics of
channels formed by PrP106–126, concluding that it was
directly incorporated into lipid bilayers and formed cation
selective, copper-sensitive ion channels [86]. They also
revealed that quinacrine, a potent therapeutic drug, possibly
blocks amyloid channels induced by PrP106–126.
The aggregation and ﬁbrillation of α-synuclein has been
implicated in the formation of abnormal inclusions, termed
Lewy bodies, and the etiology of dementia with Lewy bodies
(DLB) [87]. Nonamyloid component (NAC), a fragment
peptide of α-synuclein, accumulates in Alzheimer’s senile
plaques and causes apoptotic neuronal death [88]. Lashuel
et al. demonstrated by electron microscope observation that
α-synuclein forms annular pore-like structures [89].
The elongation of a polyglutamine-coding CAG triplet
repeat in the responsible genes is based on the pathogenesis
of triplet-repeat disease such as Huntington’s disease or
Machado-Joseph disease [90]. Hirakura et al. reported that6 International Journal of Alzheimer’s Disease
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Figure 2: Characteristics of AβP-induced elevations in [Ca2+]i.( a )T y p i c a lt i m ec o u r s eo f[ C a 2+]i p r i o rt o2m i na n da f t e r3m i no ft h e
application of the peptide is depicted. Concentration is 10μM for all peptides used. (A) AβP(1–40); (B) AβP(40-1); (C) AβP(1–42); (D) D-
AβP(1–40). The arrow indicates the time of peptide addition. (b) and (c) Dose-dependence of the increase in [Ca2+]i.T y p i c a lr e s p o n s e so f
[Ca2+]i inculturedneuronsfollowingexposuretovariousconcentrationsofAβP(1–40)(2.5∼10μM).Thepeakincreasein[Ca2+]i (Δ[Ca2+]i)
in each cell (b) and the latency after exposure to AβP(1–40) were analyzed in more than 50 neurons in ﬁeld of view (360 × 420μm) cultured
neurons (mean ± S.E.M., n = 300).
polyglutamine formed ion channels in lipid bilayers [91].
Human amylin (IAAP, islet amyloid peptide) forms amyloid
ﬁbrils, accumulates in the islet of patients of type 2 diabetes
mellitus, and causes cytotoxicity in islet cells or in cultured
hippocampal neurons. However, rat amylin did not cause
cytotoxicity nor form β-sheet structures, in spite of the 95%
similarity in the amino acid sequence [92]. Mirzabeko et
al. revealed that human amylin formed ion channels on
liposomes, but rat amylin did not [93]. Calcitonin is a 32-
amino acid polypeptide hormone, which is produced by the
thyroid C-cells. It is involved in calcium homeostasis and
is associated with medullary carcinoma of the thyroid [94].
Using transmission electron microscopy (TEM) observation
onliposome,Diociaiutietal.foundthatcalcitoninoligomers
exhibit annular pore-like structures [95]. Lal et al. inves-
tigated the oligomerization and conformational changes of
AβP, synuclein, amylin, and other amyloidogenic proteins
using gel electrophoresis and AFM imaging, and demon-
strated that these amyloidogenic proteins form annular
channel-like structures on bilayer membranes [96].International Journal of Alzheimer’s Disease 7
We have demonstrated that these amyloidogenic pep-
tide also cause the elevations in [Ca2+]i as well as AβP
(Figure 3(a)). A marked increase in [Ca2+]i was caused by
PrP106–126 (line (A)), human amylin (line (C)), NAC (line
(E))a n dA βP(1–40) (Figure 2(a), line (A))o rp o r e - f o r m i n g
antimicrobial peptide magainin 2 (line (F)). However,
control peptides such as peptide with random sequence
of PrP106–126 (scramble PrP106–126) (line (B))a n dr a t
amylin (line (D)) caused no remarkable changes. Further-
more, PrP106–126 and human amylin, as well as AβP(1–40),
cause disruption of liposome membranes and induce dye
release (Figure 3(b)).
These diseases are included in “conformational disease”
(protein misfolding disease)—the conformational change
of amyloidogenic proteins is suggested to be an important
determinant of its toxicity and, consequently, the develop-
ment of the disease [97]. The disease-related amyloidogenic
proteins exhibit similarities in the formation of β-pleated
sheet structures, abnormal deposition as amyloid ﬁbrils in
the tissues, and introduction of apoptotic degeneration.
As shown in Table 1, these amyloidogenic proteins exhibit
similarities in the direct incorporation into membranes, for-
mation of calcium-permeable ion channels, and induction
of abnormal elevation of [Ca2+]i. It is strongly suggested that
disruption of calcium homeostasis via unregulated amyloid
channels formed bythese disease-related proteinsmay be the
molecular basis of neurotoxicity of these diseases.
7.Role of Membrane Lipids in the Formationof
AmyloidChannels
It is widely accepted that the direct incorporation ofpeptides
into membranes and consequent channel formation is
strongly aﬀectedbythemembrane lipidcomposition, partic-
ularly the net charges of membrane surfaces and membrane
ﬂuidity. Several AβP residues (such as Arg5,L y s 16,a n dL y s 28)
have a positive charge at neutral pH, and therefore, AβP
has an aﬃnity for negatively charged phospholipids, such as
phosphatidylserine (PS) or phosphatidylglycerol (PG), but
not for neutral phospholipids, such as phosphatidylcholine
(PC) [98]. However, membrane phospholipid distribution is
asymmetrical in mammals: neutral lipids (PC, etc.) usually
exist on the outer surfaces of plasma membranes, whereas
negatively charged phospholipids (PS, etc.) exist in the inner
surfaces of the membranes. Thus, the binding of AβPt o
neuronal membrane surface may seldom occur in normal
and young brains.
Further inﬂuencing the binding of AβPt om e m -
branes are gangliosides—sialic-acid-bearing glycophospho-
lipids. Both APP and AβP are localized in detergent-
insoluble,cholesterol-, sphingomyelin-, and ganglioside-rich
lipid microdomains, termed rafts [99]. Yanagisawa et al.
ﬁrst demonstrated the existence of membrane-bound AβP
tightly bound to GM1 gangliosides in the brains of AD
patients [100]. AβP binds to GM1 gangliosides in raft-like
membranesinvitro,andGM1-boundAβPbehaveasa“seed”
and accelerate the oligomerization of AβP[ 101]. Numerous
studies have indicated the implication of gangliosides in the
oligomerization and the binding to the membrane of AβP
[102–104].
We have observed the deposition of AβP(1–40) on
ganglioside (GM1)/phospholipid (dipalmitoil phosphatidyl
choline; DPPC) monolayers by AFM imaging (Figure 4).
GM1-DPPC membranes exhibit distinctive, island-like GM1
domains embedded in the DPPC matrix [105, 106]. Aged
AβP(1–40) deposited and tightly bound to the mem-
brane surfaces and exhibited the damaged structures of
membranes, meanwhile freshly prepared AβPs h o w e df e w
changes.
We have previously demonstrated that AβPc a u s e sa
markedincreasein[Ca2+]i inalargeproportionoflong-term
(30–35 days in vitro; DIV) cultured hippocampal neurons.
However, few or no changes were observed in [Ca2+]i
in short-term (8 DIV) cultures (Figure 5(a))[ 107]. After
several days of exposure to sublethal levels of AβP(1–40) to
long-term cultured neurons, AβP binds to some restricted
hippocampal neurons and exhibits dotlike depositions on
the somata and dendrites. Meanwhile, there is no detectable
AβP deposition on the surfaces of neighboring neurons,
despite the morphological similarities of these neurons
(Figure 5(b)). Malchiodi-Albedi et al. found that lipid rafts
increased during the maturation of culture periods of pri-
mary culturedrathippocampal neurons[108].They demon-
strated that Calcitonin, an amyloidogenic peptide, causes
[Ca2+]i changes in mature raft-containing neurons, but not
in immature cultured neurons. Williamson et al. found
that AβP was not uniformly distributed over the neuronal
processes, and was colocalized with GM1 ganglioside [109].
These features are consistent with our results, and it is
possible that gangliosides in lipid rafts may regulate the
binding of AβP into membranes and its neurotoxicity.
It is widely accepted that cholesterol enhances mem-
brane stiﬀness, decreases membrane ﬂuidity, and inhibits
pore formation by pore-forming peptides [110]. Lin and
Kagan found that cholesterol inhibits channel formation by
AβP[ 111]. Cholesterol blocks AβP-induced elevations in
[Ca2+]i [41, 72], aggregation of AβP-containing liposomes
[112],andAβPcytotoxicity[112,113].Moreover,cholesterol
attenuates AβP-induced membrane-disordering eﬀects and
calcium increase [114]. Considering that apolipoprotein E,
involved in cholesterol transport and metabolism, is present
in the senile plaques and NFTs in AD brains and its
polymorphism is a risk factor of AD [115], the implication
of cholesterol in AD pathogenesis is crucial.
To determine the implications of membrane properties
in the formation of amyloid channels, we tested the eﬀects
of several lipophilic substances, which modulate membrane
properties, on AβP-induced [Ca2+]i elevations [74, 107].
Phloretin, a plant-derived ﬂavonoid, decreases membrane
dipole potential, and inhibits the electrostatic interaction
between AβP and membrane lipids, and attenuates AβP-
induced neurotoxicity [116]. Meanwhile, 6-ketocholestanol
increases the magnitude of the membrane dipole potential
and decreases membrane ﬂuidity [117]. Figure 6 shows that
the preadministration of phloretin and cholesterol markedly
inhibited AβP-induced [Ca2+]i elevations; meanwhile, 6-
ketocholestanoldidnot causesigniﬁcant changes, despitethe8 International Journal of Alzheimer’s Disease
1min
Ca2+(100nM)
(D)
(A)
(B)
(C)
(E)
(F)
(a)
02 0 4 0 6 0 80 100
0
20
40
60
80
100
D
y
e
r
e
l
e
a
s
e
(
%
)
120 140
Time (min)
(b)
Figure 3: Eﬀects ofamyloidogenicproteins on membranedisruption and [Ca2+]i elevations.(a) Eﬀects of amyloidogenicproteins and their
analogueson[Ca2+]i.T ypicaltimecourseof[Ca
2+]i priorto2minandafter3minoftheapplicationofthepeptide isdepicted. Concentration
is 10μM for all peptides used. (A) PrP106–126;(B) scramblePrP106–126;(C) humanamylin;(D) ratamylin;(E) NAC; (F) magainin 2.The
arrow indicates the time of peptide addition. (b) Membrane disruption by amyloidogenic peptides. AβP(1–40) (closed circle), PrP106–126
(closed square), and human amylin (open circle) (each 10μM) were added to negatively charged liposomes containing carboxyﬂuorescein.
The ratio of DPPC (dipalmitoil phosphatidyl choline) : CHOL (cholesterol) : DPPG (dipalmitoilphosphatidyl glycerol) in the liposomewas
3:4:3. The temporal changes of the ﬂuorescence intensity were monitored. The ratio of the released ﬂuorescent dye (carboxy ﬂuoresein;
CF) compared to the total amount of CF was described as the percentage of membrane disruption.International Journal of Alzheimer’s Disease 9
21
1.5
1.5
0
0
0 (µm)
(µm)
(nm)
500nm
1.47 × 1.47µn × 36.7nm
(a)
16
16
0
0
0 (µm)
(µm)
(nm)
500nm
1.51 × 1.51µn × 16.3nm
(b)
0
0
0
37
1.4
1.4
(µm)
(µm)
(nm)
500nm
1.43 × 1.43µn × 36.7nm
(c)
21
0
0
0 1.5
1.5
(µm)
(µm)
(nm)
500nm
1.78 × 1.87µn × 21.3nm
(d)
Figure 4: AFM images of AβP(1–40) on monolayer membranes. Lipid monolayer membranes composed by DPPC (a) or ganglioside
GM1-DPPC (dipalmitoil phosphatidyl choline) (b)∼(d) were prepared by bath sonication and reconstitution on mica plates. The ratio
of GM1:DPPC was 8:2. AFM images were obtained after the exposure to freshly prepared AβP(1–40) (c) or aged AβP(1–40) (d). Scale area:
1.5 × 1.5μm.
0
50
100
150
200
250
300
350
400
0 5 10 15 20 25 30 35 40
Δ
[
C
a
2
+
]
i
(
n
M
)
Days in vitro(DIV)
(a) (b)
Figure 5: (a) Maturation-dependent increase in AβP-induced [Ca2+]i changes in primary cultured neurons. (b) Heterogeneous aﬃnity of
AβP to mature cultured hippocampal neurons. Long-term cultured rat hippocampal neurons were exposed to 1μMo fA βP(1–40) at 29DIV
and ﬁxed after 4 days.Neurons were double immunostainedby anti-MAP2antibody (Texas Red, red) and anti-AβP antibody (FITC, green),
and observed by Laser confocal microscopy. Scale bar represents 50μm. (modiﬁed from [100]).10 International Journal of Alzheimer’s Disease
Table 1: Characteristics of amyloidogenicproteins and the related peptides.
Disease Amyloidogenic protein or its fragment peptide and
the primary sequence
β-sheet
formation Cytotoxicity Channel
formation
[Ca
2+]i
rise
Alzheimer’s disease
AβP(1–40)
DAEFRHDSGYEVHHQKLVFFAE ++++
DVGSNKGAIIGLMVGGVV
AβP(40-1)
VVGGVMLGIIAGKNSGVDEAFFV ––––
LKQHHVEYGSDHRFEAD
AβP(25-35)
DVGSNKGAII + + + +
AβP(1–42)
DAEFRHDSGYEVHHQKLVFFAEDV ++++
GSNKGAIIGLMVGGVVIA
Prion disease
PrP106–126 (prion protein fragment)
KTNMKHMAGAAAAGAVVGGLG + + + +
Scramble PrP106–126
N G A K A L M G G H G A T K V M V G A A A ––––
Parkinson’s disease
(DLB; diseases with
Lewy bodies)
α-synuclein NAC (a fragment of α-synuclein)
EQVTNVGGAVVTGVTAVAQKTVEGAGSIAA-
ATGFV ++++
Triplet-repeat
disease
Polyglutamine
QQQQQQQQ— + + + n.d.
Diabetes mellitus
Human amylin
KCNTATCATQRLANFLVHSSNNFGAILSST-
NVGSNTY ++++
Rat amylin
KCNTATCATQRLANFLVRSSNNLGPVLPPT-
NVGSNTY ––––
Medullary carcinoma
of the thyroid
Calcitonin
CGNLSTCMLGTYTQDFNKFHTFPQTAIGVG-
AP ++++
n.d.: not determined.
structural similarity to cholesterol. Therefore, as expected
from other ﬁndings, the net charges of membrane surfaces
andthemembrane ﬂuidityplaycrucialroles intheelevations
of [Ca2+]i caused by AβP.
Furthermore, numerous studies have demonstrated that
gangliosides and cholesterol are implicated in the channel
formation of other amyloidogenic proteins. Lipid rafts are
considered to be the compartment where the conforma-
tional change of PrP occurs [118]. Gangliosides inﬂuence
the β-sheet formation of PrP106–126 [119]a n dh u m a n
amylin [120], or the channel formation of α-synuclein
[121]. Cholesterol also inhibitschannel formation by human
amylin [122].
8.Possible CandidatefortheTreatmentofAD
The search for protective agents against AβPn e u r o t o x i c i t y
is of great importance. Such agents include inhibitors of
AβP oligomerization, inhibitors of BACE or γ-secretase,
AβP vaccines, and chelators of trace metals; all have been
proposed to be eﬀective in the treatment of AD.
Here, we have focused on substances that inhibit the
formation of amyloid channels. As discussed, the elevation
of [Ca2+]i by permeation through amyloid channels is
considered to be the primary event of AβPn e u r o t o x i c i t y ;
therefore, such compounds could serve as the seed of new
eﬀective drugs with fewer adverse eﬀects.
Zn2+ ion, which is abundant in vesicles of presynaptic
terminals and is secreted into synaptic clefts with neuronal
excitation,inhibitsthecurrentsinducedbyamyloid channels
[52, 54, 70]. Zn2+ b i n d st oH i sr e s i d u e so fA βP: Arispe et al.
found that histidine-related peptide derivatives such as His-
His or polyhistidine are eﬀective in the inhibition of amyloid
channels, the attenuation of AβP-induced [Ca2+]i changes,
and the protection of neurons from AβP toxicity [123,
124]. They developed several small amphiphilic pyridinium
derivatives which inhibit formation of AβP channels and its
neurotoxicity [8, 125].
In line with the search for protective agents, we have
screened compounds, which inﬂuence membrane properties
and inhibit formations of amyloid channels, by observing
the AβP-induced Ca2+ inﬂux. Among those tested, weInternational Journal of Alzheimer’s Disease 11
Cholesterol (Chol)
Phloretin (PH)
6-ketocholestanol (6KC)
H
H
H
H
H H
H
H
HO
HO
HO
OH
OH
OH
O
O
(a)
AβPA βPA βPA βP
+ ++
Chol PH 6K C
∗∗
∗∗
0
100
200
300
400
500
600
Δ
[
C
a
2
+
]
i
(
n
M
)
(b)
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found that several lipophilic substances, such as 17β-
estradiol, 17α-estradiol, and neurosteroids (including dehy-
droepiandrosterone [DHEA], DHEA sulfate [DHEA-S], and
pregnenolone) signiﬁcantly inhibit AβP-induced [Ca2+]i ele-
vation [74, 107]. 17β-estradiol, a female hormone, is neuro-
protective and aﬀects membrane ﬂuidity [126]. Considering
that both 17β-estradiol and 17α-estradiol inhibit AβP-
induced [Ca2+]i elevation, the inhibition may not depend
on their genomic actions but on their membrane-modifying
eﬀects. Neurosteroids are steroid hormones synthesized de
novo in the central nervous system from cholesterol or from
peripheral steroid precursors [127]. Several lines of evidence
suggest that neurosteroids modulate various functions of the
brain and exhibit neuroprotective activities [128]. Consid-
ering that concentrations of plasma DHEA are reduced in
AD patients [129], the implication of neurosteroids in the
pathogenesis of AD may be important.
9.AmyloidChannel Hypothesis
Based on the results of our studies, together with those of
otherstudies, we propose the following hypothetical scheme:
that unregulated calcium inﬂux via amyloid channels may
underlie the molecularmechanism of AβPn e u r o t o x i c i tya n d
the pathogenesis of AD (Figure 7).
AβPs are normally secreted from APP, which exists in
t h es y n a p s e ,i n t ot h ec e r e b r o s p i n a lﬂ u i do rs y n a p t i cc l e f t s .
Secreted AβPs are degraded proteolytically by proteases,
such as neprilysin [130], within a short period. However,
upregulation of the AβP secretion from APP, or an increased
ratio of AβP(1–42) to AβP(1–40) may render AβPs liable
to be retained in the brain. Mutations of APP or presenilin
gene promote this process. The binding of AβPt on e u r o n a l
membranes is the important determinant for its neurotoxic-
ity. Since AβP seldom binds to normal neuronal membranes
withneutralphospholipidssuchasPCusuallyexisting onthe
outersurfaces ofplasmamembranes, itwouldbelesslikelyto
occur in the brains of normal and young subjects. However,
whentheasymmetrical distributionisdisruptedbyapoptotic
conditions or aging and negatively charged phospholipids
such as PS appear on the outer membrane surfaces, AβPs
can bind to membrane surfaces (Figure 7(a)). Furthermore,
considering that AβPs have aﬃnity to PS in inner membrane
surfaces, the intraneuronal accumulation of AβPs may be
more toxic [131]. Gangliosides also contribute to the net
charge of the outer membrane surface and to the binding to
AβPs (Figure 7(b)). Microcircumstances on the membranes,
such as lipid rafts, provide suitable locations which facilitate
this process from (A) to (B). After incorporation into
the membrane, the conformation of AβPs change and the
accumulated AβPs aggregate on the membranes. The ratio
of cholesterol to phospholipids in the membrane may alter
membrane ﬂuidity, thereby aﬀecting these processes. Finally,
aggregated AβP oligomers form ion channels leading to the
various neurodegenerative processes (Figure 7(C)).
The velocity of channel formation will be regulated by
the binding of AβP on membranes and its concentration.
Considering that soluble oligomers are more toxic compared
t om o n o m e ro rﬁ b r i l s[ 26, 27, 65], it is provable that12 International Journal of Alzheimer’s Disease
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AβP oligomerization in vitro accelerates the velocity from
(A) to (B), and enhances the formation of tetrameric or
hexameric pores on membranes. Indeed, O’Nuallain et al.
demonstrated that AβP dimers formed toxic protoﬁbrils
more rapidly compared to monomer [132]. However, the
proposed structures of AβP channels in membrane mimic
conditions are not always similar to the structures formed in
the solution such as protoﬁbrils or soluble oligomers. Thus,
the conformational changes in membranes may also be
signiﬁcant.
These processes required for channel formation ((A) to
(C)) may require a long life span in general and determine
the rate of the entire process. Unlike endogenous Ca2+
channels, these AβP channels are not regulated by usual
blockers. Thus, once formed on membranes, a continuous
ﬂow of [Ca2+]i is initiated.
Disruptionof calciumhomeostasis triggers several apop-
totic pathways and promotes numerous degenerative pro-
cesses,includingfreeradicalformationandtauphosphoryla-
tion,thereby acceleratingneuronaldeath.The source ofCa2+
may be from extracellular or intracellular Ca2+ store (ER or
mitochondoria). Considering that presenilins are involvedin
the capacitive calcium entry, in Ca2+ homeostasis in ER or in
mitochondoria [46–49] and the implication of ER stress inInternational Journal of Alzheimer’s Disease 13
ADandotherneurodegenerativediseases[133],mutationsof
presenilins may inﬂuence these pathways. Free radicals also
induce membrane disruption, by which unregulated calcium
inﬂux is further ampliﬁed. The disruption of calcium
homeostasis inﬂuences the production and processing of
APP. Thus, a vicious spiral of neurodegeneration is initiated.
Meanwhile, zinc ions, which are secreted into synaptic
clefts in a neuronal activity-dependent manner, inhibit AβP-
induced Ca2+ entry, and thus have a protective function in
AD.
This hypothesis explains the long delay in AD develop-
ment; AD occurs only in senile subjects despite the fact that
AβPs are also normally secreted in younger or in normal
subjects. AD is multifactorial disease. Various environmental
factors, such as foods (cholesterol contents) or trace metals,
as well as genetic factors will inﬂuence these processes
and contribute to AD pathogenesis. The amyloid channel
hypothesis could explain eﬀects of environmental factors
such as cholesterol and other various aspects of AD patho-
genesis and may aid in improving a precise understanding
of AD and in the development of drugs for AD treatment.
Although the ﬁndings of channel-like structures in vivo
[66, 68], it is diﬃcult to determine whether these amyloid
channels really exist in the brains of AD patients. Therefore,
further in vivo studies are necessary.
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